Why the study?
Elevated PCSK9 during cardiac ischemia/reperfusion instigates inflammatory and oxidative processes, but the effects of PCSK9 inhibitors on the heart during ischemia/reperfusion injury had not been investigated.
Does PCSK9 inhibitor administration improve cardiac function and reduce infarct size in rats with ischaemia/reperfusion injury?
Does PCSK9 inhibitor administration improve cardiac function and reduce infarct size in rats with ischaemia/reperfusion injury?
Answers are grounded in this paper and cite their sources.
Pre-ischaemic administration of a PCSK9 inhibitor provides cardioprotection against ischaemia/reperfusion injury in a rat model, suggesting benefits beyond lipid-lowering effects.
During acute cardiac ischaemia/reperfusion (I/R), an increased plasma proprotein convertase subtilisin/kexin 9 (PCSK9) level instigates inflammatory and oxidative processes within ventricular myocytes, resulting in cardiac dysfunction. Therefore, PCSK9 inhibitor (PCSK9i) might exert cardioprotection against I/R injury. However, the effects of PCSK9i on the heart during I/R injury have not been investigated. The effects of PCSK9i given at different time-points during I/R injury on left ventricular (LV) function were investigated. Male Wistar rats were subjected to cardiac I/R injury and divided into 3 treatment groups (n = 10/group): pre-ischaemia, during ischaemia and upon onset of reperfusion. The treatment groups received PCSK9i (Pep2-8, 10 μg/kg) intravenously. A control group (n = 10) received saline solution. During the I/R protocol, arrhythmia scores and LV function were determined. Then, the infarct size, mitochondrial function, mitochondrial dynamics and level of apoptosis were determined. PCSK9i given prior to ischaemia exerted cardioprotection through protection of cardiac mitochondrial function, decreased infarct size and improved LV function, compared with control. PCSK9i administered during ischaemia and upon the onset of reperfusion did not provide any of those benefits. PCSK9i administered before ischaemia exerts cardioprotection, as demonstrated by the attenuation of infarct size and cardiac arrhythmia during cardiac I/R injury. The attenuation is associated with improved mitochondrial function and connexin43 phosphorylation, leading to improved LV function.
No takes yet. Share an insight, caveat, or question.
Palee et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: